Developer docs
API playgroundTry for free, no card

Search company profiles

BioOrbit

Full company profile

uuid0006ys6

Namestring
BioOrbit
Legal namestring
BioOrbit Ltd
Websiteurl
bioorbit.space
Company typeenum
Private
Founded yearint
2023
Descriptiontext

BioOrbit is a London-based space biotechnology company founded in 2023 that develops proprietary hardware for microgravity protein crystallization to improve pharmaceutical manufacturing of biologics. The company has built a three-tier product platform comprising BOX-T for research validation, BOX-S for preclinical and clinical development, and BOX-R for industrial-scale mass manufacture, all designed for dual-environment operation on Earth and in orbit. In May 2026, BioOrbit launched Box-E, a compact drug-crystallization unit, to the International Space Station aboard a SpaceX rocket and subsequently achieved record-breaking protein crystal production at one to two orders of magnitude above prior space-based attempts, with crystals reaching approximately 500μm.

The company generates revenue through pharmaceutical manufacturing services for biologics developers, with professional-services-style engagements managed via a "Book a Project" contact form, alongside potential future technology licensing. Its target customers are pharmaceutical and biotech companies developing protein-based drugs, monoclonal antibodies, and vaccines, with primary use cases in oncology (enabling home self-injectable cancer treatments instead of hospital IV infusions) and rare disease biologics. BioOrbit's commercial channels are direct enterprise sales to international pharma and biotech counterparties, supported by marketing through major tech conferences such as SLUSH and London Tech Week and earned media coverage.

BioOrbit is backed by a £9.8 million seed round co-led by LocalGlobe and Breega, described as the world's largest seed round for in-space manufacturing, with additional capital from a £250,000 UK Space Agency PHARM feasibility study. Strategic partnerships include the UK Space Agency, MHRA, Civil Aviation Authority, and an MoU with commercial space station developer Vast to continue microgravity research beyond ISS retirement. The company was recognized as one of Tech Nation's Future Fifty companies in 2025 and is led by CEO and co-founder Dr. Katie King alongside President Dr. Molly Mulligan, CSO Dr. Kenneth Savin, and CTO Jacques Fossey, with approximately 15-16 employees.

Short descriptiontext

BioOrbit is a London-based space biotechnology company building a proprietary microgravity protein crystallization platform (BOX-T, BOX-S, BOX-R, and ISS-deployed Box-E) for pharmaceutical manufacturing of biologics, targeting oncology and rare disease drug developers seeking injectable, home-administered formulations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microgravity crystallization, in-space biopharmaceutical manufacturing, protein drug crystallization, biologics formulation services, orbital pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Space Biopharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Manufacturing Services
TypeProfessional Services
Description

BioOrbit provides microgravity crystallization services to pharmaceutical companies, enabling transformation of high-value protein-based drugs into injectable formats. Revenue likely generated through service contracts, research partnerships, and potentially milestone-based payments for drug development programs.

startupsmagazine.co.uk
2Technology Licensing
TypeLicensing Royalties
Description

Potential future revenue from licensing proprietary microgravity crystallization technology and processes to pharmaceutical partners for drug reformulation and manufacturing.

trendhunter.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioOrbit develops and operates a proprietary scalable microgravity crystallization platform for pharmaceutical manufacturing of biologics. The platform comprises three staged systems (BOX-T for research, BOX-S for preclinical/clinical, BOX-R for mass manufacture) plus the Box-E orbital unit flown to the ISS. The company delivers microgravity crystallization services to pharmaceutical companies, enabling transformation of high-value protein-based drugs into injectable formats for home administration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Protein crystals reaching 500μm in space (compared to significantly smaller on Earth)
+2 more records
Product overview1 text field

BioOrbit is building the leading scalable crystallisation platform for complex biologics, comprising a proprietary product line designed for dual-environment operation: BOX-T for research validation in microgravity, BOX-S for preclinical and clinical access, and BOX-R for mass manufacture. The company deploys Box-E, a compact ISS crystallisation unit, for orbital drug manufacturing experiments. The platform enables transformation of high-value protein-based drugs into injectable formats for home administration, with applications in oncology care shifting from hospital to home.

Product and service5 records
1BOX-T (Research Platform)
CategoryMicrogravity Crystallization Platform - Research Stage
Description

Research-grade crystallization unit designed and built to validate crystallization in microgravity environments. Used by pharmaceutical researchers to test and validate the feasibility of microgravity crystallization for biologic drug candidates.

2BOX-S (Pre/Clinical Platform)
CategoryMicrogravity Crystallization Platform - Pre/Clinical Stage
Description

Preclinical and clinical-grade crystallization platform that unlocks access for biologic drug development through preclinical and clinical stages. Used by pharmaceutical companies to produce crystallization data and material for regulatory submissions.

3BOX-R (Mass Manufacture Platform)
CategoryMicrogravity Crystallization Platform - Mass Manufacture Stage
Description

Industrial-scale crystallization platform that unlocks mass manufacture for large-scale production of crystallized biologics. Used by pharmaceutical companies for commercial-scale microgravity crystallization of protein-based drugs.

4Box-E Orbital Manufacturing Unit
CategoryOrbital Drug Manufacturing Unit
Description

Compact orbital drug-crystallisation unit deployed to the International Space Station to grow ultra-pure protein crystals in microgravity for biologic drugs, including self-injected cancer treatments. Demonstrated record-breaking protein crystal production scale on the ISS.

5Microgravity Crystallization Services
CategoryPharmaceutical Manufacturing Services
Description

Bespoke microgravity crystallization services provided to pharmaceutical and biotech companies developing protein-based drugs. Enables transformation of high-value biologics into injectable formats for home administration, with applications in oncology care shifting from hospital to home. Engagements initiated via 'Book a Project' contact channel.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Vast
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Commercial space station company Vast signed MoU with BioOrbit to enable biomedical research work on Vast's commercial station after ISS retirement. BioOrbit will continue and expand microgravity research currently conducted on the ISS through this partnership.

spacenews.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

UK Space Agency funding £250,000 feasibility study for BioOrbit (PHARM study) to develop in-orbit crystallization of biologic drugs for cancer treatments. Study runs until March 2026, part of £2.2m government investment in space biopharma.

3MHRA (Medicines and Healthcare products Regulatory Agency)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Joint regulatory roadmap enabling in-orbit pharmaceutical manufacturing, providing supportive regulatory environment for BioOrbit's drug development activities.

gov.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Partnership to develop licensing guidance for in-orbit manufacturing platforms and re-entry regulatory sandbox supporting space pharmaceutical development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Peers8 records
TypeEmerging player
Description

LambdaVision uses microgravity to produce a protein-based artificial retina and is exploring microgravity-enabled biotech manufacturing. It is an emerging player with thematic overlap to BioOrbit's space-based protein crystallization platform for therapeutic applications.

TypeDirect peer
Description

Varda Space Industries builds orbital factories for in-space pharmaceutical manufacturing, including microgravity-grown drug crystals. It is the closest direct peer to BioOrbit, sharing the same core thesis of producing pharmaceutical-grade crystals in orbit for terrestrial drug formulation.

TypeDirect peer
Description

Space Tango operates microgravity research platforms on the ISS for biotech and pharma customers, including crystallization and bioprocessing experiments. It is directly comparable to BioOrbit in providing microgravity R&D infrastructure for biological and pharmaceutical applications.

TypeBroad incumbent
Description

Redwire is a publicly traded space infrastructure company with a portfolio spanning in-space biotech, manufacturing, and orbital hardware (including the former Made In Space). It is a broad incumbent competing with BioOrbit across microgravity biotech payloads and on-orbit manufacturing platforms.

TypeDirect peer
Description

SpacePharma develops miniaturized microgravity laboratories for pharmaceutical and biological research, both on the ISS and via autonomous satellites. It is directly comparable to BioOrbit in operating end-to-end microgravity experimentation infrastructure for pharma and biotech.

TypeEmerging player
Description

BioServe Space Technologies (University of Colorado) is a long-standing microgravity life sciences and biotech research payload developer that has flown dozens of pharma-relevant experiments on the ISS. It is comparable as a peer institution developing microgravity biotech research infrastructure.

TypeEmerging player
Description

Encapsulate develops automated tumor-on-a-chip platforms and has conducted microgravity-enabled drug screening and validation experiments. It is an emerging player intersecting BioOrbit's downstream use case of validating biologics via space-enabled biology platforms.

TypeDirect peer
Description

Made In Space pioneered in-space additive manufacturing and is now part of Redwire's space biotechnology portfolio. It is a direct peer to BioOrbit in demonstrating scalable, on-orbit manufacturing of high-value materials, with overlapping capabilities in space-based production hardware.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioOrbit

Space Biopharmaceutical Manufacturingbioorbit.space

BioOrbit is a London-based space biotechnology company building a proprietary microgravity protein crystallization platform (BOX-T, BOX-S, BOX-R, and ISS-deployed Box-E) for pharmaceutical manufacturing of biologics, targeting oncology and rare disease drug developers seeking injectable, home-administered formulations.

What BioOrbit does

BioOrbit is a London-based space biotechnology company founded in 2023 that develops proprietary hardware for microgravity protein crystallization to improve pharmaceutical manufacturing of biologics. The company has built a three-tier product platform comprising BOX-T for research validation, BOX-S for preclinical and clinical development, and BOX-R for industrial-scale mass manufacture, all designed for dual-environment operation on Earth and in orbit. In May 2026, BioOrbit launched Box-E, a compact drug-crystallization unit, to the International Space Station aboard a SpaceX rocket and subsequently achieved record-breaking protein crystal production at one to two orders of magnitude above prior space-based attempts, with crystals reaching approximately 500μm.

The company generates revenue through pharmaceutical manufacturing services for biologics developers, with professional-services-style engagements managed via a "Book a Project" contact form, alongside potential future technology licensing. Its target customers are pharmaceutical and biotech companies developing protein-based drugs, monoclonal antibodies, and vaccines, with primary use cases in oncology (enabling home self-injectable cancer treatments instead of hospital IV infusions) and rare disease biologics. BioOrbit's commercial channels are direct enterprise sales to international pharma and biotech counterparties, supported by marketing through major tech conferences such as SLUSH and London Tech Week and earned media coverage.

BioOrbit is backed by a £9.8 million seed round co-led by LocalGlobe and Breega, described as the world's largest seed round for in-space manufacturing, with additional capital from a £250,000 UK Space Agency PHARM feasibility study. Strategic partnerships include the UK Space Agency, MHRA, Civil Aviation Authority, and an MoU with commercial space station developer Vast to continue microgravity research beyond ISS retirement. The company was recognized as one of Tech Nation's Future Fifty companies in 2025 and is led by CEO and co-founder Dr. Katie King alongside President Dr. Molly Mulligan, CSO Dr. Kenneth Savin, and CTO Jacques Fossey, with approximately 15-16 employees.

BioOrbit firmographics

Firmographics
Name
BioOrbit
Legal name
BioOrbit Ltd
Website
https://bioorbit.space
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
BioOrbit is a London-based space biotechnology company building a proprietary microgravity protein crystallization platform (BOX-T, BOX-S, BOX-R, and ISS-deployed Box-E) for pharmaceutical manufacturing of biologics, targeting oncology and rare disease drug developers seeking injectable, home-administered formulations.
Ownership category
akta.pro rank

BioOrbit industry classification

Industry
Product category
Space Biopharmaceutical Manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services

Keywords

  • Microgravity crystallization
  • In-space biopharmaceutical manufacturing
  • Protein drug crystallization
  • Biologics formulation services
  • Orbital pharmaceutical manufacturing

Where BioOrbit is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

BioOrbit business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Manufacturing Services: BioOrbit provides microgravity crystallization services to pharmaceutical companies, enabling transformation of high-value protein-based drugs into injectable formats. Revenue likely generated through service contracts, research partnerships, and potentially milestone-based payments for drug development programs.
  2. Technology Licensing: Potential future revenue from licensing proprietary microgravity crystallization technology and processes to pharmaceutical partners for drug reformulation and manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

BioOrbit product offering

Product offering

Core offering

BioOrbit develops and operates a proprietary scalable microgravity crystallization platform for pharmaceutical manufacturing of biologics. The platform comprises three staged systems (BOX-T for research, BOX-S for preclinical/clinical, BOX-R for mass manufacture) plus the Box-E orbital unit flown to the ISS. The company delivers microgravity crystallization services to pharmaceutical companies, enabling transformation of high-value protein-based drugs into injectable formats for home administration.

Product overview

BioOrbit is building the leading scalable crystallisation platform for complex biologics, comprising a proprietary product line designed for dual-environment operation: BOX-T for research validation in microgravity, BOX-S for preclinical and clinical access, and BOX-R for mass manufacture. The company deploys Box-E, a compact ISS crystallisation unit, for orbital drug manufacturing experiments. The platform enables transformation of high-value protein-based drugs into injectable formats for home administration, with applications in oncology care shifting from hospital to home.

Differentiator

Problem solved

Functional benefit

Products and services

  • BOX-T (Research Platform) Research-grade crystallization unit designed and built to validate crystallization in microgravity environments. Used by pharmaceutical researchers to test and validate the feasibility of microgravity crystallization for biologic drug candidates.
  • BOX-S (Pre/Clinical Platform) Preclinical and clinical-grade crystallization platform that unlocks access for biologic drug development through preclinical and clinical stages. Used by pharmaceutical companies to produce crystallization data and material for regulatory submissions.
  • BOX-R (Mass Manufacture Platform) Industrial-scale crystallization platform that unlocks mass manufacture for large-scale production of crystallized biologics. Used by pharmaceutical companies for commercial-scale microgravity crystallization of protein-based drugs.
  • Box-E Orbital Manufacturing Unit Compact orbital drug-crystallisation unit deployed to the International Space Station to grow ultra-pure protein crystals in microgravity for biologic drugs, including self-injected cancer treatments. Demonstrated record-breaking protein crystal production scale on the ISS.
  • Microgravity Crystallization Services Bespoke microgravity crystallization services provided to pharmaceutical and biotech companies developing protein-based drugs. Enables transformation of high-value biologics into injectable formats for home administration, with applications in oncology care shifting from hospital to home. Engagements initiated via 'Book a Project' contact channel.

Quantifiable outcome

  • Protein crystals reaching 500μm in space (compared to significantly smaller on Earth)
  • +2 more outcomes

Companies that use BioOrbit

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

BioOrbit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioOrbit partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • VastcoreStrategic or Co-development Partner · 24 June 2026Commercial space station company Vast signed MoU with BioOrbit to enable biomedical research work on Vast's commercial station after ISS retirement. BioOrbit will continue and expand microgravity research currently conducted on the ISS through this partnership.
  • UK Space AgencycoreStrategic or Co-development Partner · 5 March 2026UK Space Agency funding £250,000 feasibility study for BioOrbit (PHARM study) to develop in-orbit crystallization of biologic drugs for cancer treatments. Study runs until March 2026, part of £2.2m government investment in space biopharma.
  • MHRA (Medicines and Healthcare products Regulatory Agency)coreStrategic or Co-development Partner · 5 March 2026Joint regulatory roadmap enabling in-orbit pharmaceutical manufacturing, providing supportive regulatory environment for BioOrbit's drug development activities.
  • Civil Aviation AuthoritycoreStrategic or Co-development Partner · 5 March 2026Partnership to develop licensing guidance for in-orbit manufacturing platforms and re-entry regulatory sandbox supporting space pharmaceutical development.

Scale indicators5 records

Recent moves6 records

BioOrbit competitors and assessment

Company assessment

Emerging players

  • LambdaVision: LambdaVision uses microgravity to produce a protein-based artificial retina and is exploring microgravity-enabled biotech manufacturing. It is an emerging player with thematic overlap to BioOrbit's space-based protein crystallization platform for therapeutic applications.
  • BioServe Space Technologies: BioServe Space Technologies (University of Colorado) is a long-standing microgravity life sciences and biotech research payload developer that has flown dozens of pharma-relevant experiments on the ISS. It is comparable as a peer institution developing microgravity biotech research infrastructure.
  • Encapsulate: Encapsulate develops automated tumor-on-a-chip platforms and has conducted microgravity-enabled drug screening and validation experiments. It is an emerging player intersecting BioOrbit's downstream use case of validating biologics via space-enabled biology platforms.

Direct peers

  • Varda Space Industries: Varda Space Industries builds orbital factories for in-space pharmaceutical manufacturing, including microgravity-grown drug crystals. It is the closest direct peer to BioOrbit, sharing the same core thesis of producing pharmaceutical-grade crystals in orbit for terrestrial drug formulation.
  • Space Tango: Space Tango operates microgravity research platforms on the ISS for biotech and pharma customers, including crystallization and bioprocessing experiments. It is directly comparable to BioOrbit in providing microgravity R&D infrastructure for biological and pharmaceutical applications.
  • SpacePharma: SpacePharma develops miniaturized microgravity laboratories for pharmaceutical and biological research, both on the ISS and via autonomous satellites. It is directly comparable to BioOrbit in operating end-to-end microgravity experimentation infrastructure for pharma and biotech.
  • Made In Space (Redwire subsidiary): Made In Space pioneered in-space additive manufacturing and is now part of Redwire's space biotechnology portfolio. It is a direct peer to BioOrbit in demonstrating scalable, on-orbit manufacturing of high-value materials, with overlapping capabilities in space-based production hardware.

Broad incumbents

  • Redwire Corporation: Redwire is a publicly traded space infrastructure company with a portfolio spanning in-space biotech, manufacturing, and orbital hardware (including the former Made In Space). It is a broad incumbent competing with BioOrbit across microgravity biotech payloads and on-orbit manufacturing platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioOrbit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioOrbit leadership team

Management profile

Number of profiles

Profiles8 records

BioOrbit funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioOrbit M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioOrbit

What does BioOrbit do?

BioOrbit develops and operates a proprietary scalable microgravity crystallization platform for pharmaceutical manufacturing of biologics. The platform comprises three staged systems (BOX-T for research, BOX-S for preclinical/clinical, BOX-R for mass manufacture) plus the Box-E orbital unit flown to the ISS. The company delivers microgravity crystallization services to pharmaceutical companies, enabling transformation of high-value protein-based drugs into injectable formats for home administration.

Is BioOrbit a public or private company?

BioOrbit is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioOrbit founded?

BioOrbit was founded in 2023. It employs 11 to 50 people.

Where is BioOrbit based?

BioOrbit is headquartered in London, United Kingdom, in the Europe region.

How does BioOrbit make money?

Two revenue lines are on record. Pharmaceutical Manufacturing Services are the primary driver. The others are technology Licensing.

Who are BioOrbit's main competitors?

Emerging players on record are LambdaVision, BioServe Space Technologies and Encapsulate. Direct peers are Varda Space Industries, Space Tango, SpacePharma and Made In Space (Redwire subsidiary). Redwire Corporation is listed as a broad incumbent.

Does BioOrbit have an API?

No public API is recorded for BioOrbit.

What industry is BioOrbit in?

BioOrbit's product category is Space Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EuropaWireUK BioOrbit Completes ISS Protein-Crystal Mission and Secures £9.8 Million to Advance Space-Based Cancer MedicinesBioOrbit completed a six-week ISS mission using its Baby BOX-E platform to produce protein crystals in microgravity. The company secured £9.8 million in seed funding and aims to develop concentrated cancer medicines for home injection, potentially reducing hospital visits. It plans to establish a space-based pharmaceutical manufacturing facility within a decade.ScienceDreams of making drugs and tissues in space get closer to realityA Science article reports that falling launch costs and mature orbital labs are enabling startups like Varda Space Industries, LambdaVision and BioOrbit to manufacture drugs, protein films and organoids in microgravity. Launch costs per kilogram have fallen from over $15,000 in 2000 to under $4,000 in 2025, projected to drop another 50% by 2030. Varda has seven flights scheduled for 2027 and 10 for 2028.MarketScreenerBioOrbit CEO on Developing Cancer Treatments in Zero GravityBioOrbit, a space biotechnology company, achieved a record-breaking milestone by producing protein crystals in microgravity on the International Space Station, marking the largest scale production of protein crystals in space by one to two orders of magnitude. CEO and cofounder Katie King discussed this achievement as part of the company's efforts to advance cancer treatment development using the unique properties of space-based protein crystal growth.TechnologymagazineCan AI Really Improve the NHS? 3 Healthtech Leaders Weigh InThree healthtech leaders participated in a roundtable discussion on how AI and emerging technologies can address the NHS's operational challenges, including a 7.2 million patient waiting list and severe diagnostic imaging backlogs. Scan.com's UK Managing Director Dr. Lizzie Tuckey discussed AI-assisted radiology workflows achieving up to 50% scanner utilisation improvements, while Tandem Health's Dr. Katie Baker outlined AI deployment across NHS trusts and 97% of UK primary care. BioOrbit's Founder and CEO Dr. Katie King presented space-based drug manufacturing technology that could enable home-administered cancer treatments, potentially reducing reliance on hospital visits.The GuardianFinal frontier for meds? UK startup sends drug-making into spaceUK startup BioOrbit launched Box-E, a compact drug-crystallisation unit, to the International Space Station on a SpaceX rocket from Florida on 15 May to grow ultra-pure protein crystals in microgravity for self-injected cancer drugs. The company has raised £9.8m from investors including LocalGlobe and Breega, and secured a £250,000 contract from the UK Space Agency, to develop technology that could enable home injections instead of hospital IV infusions. BioOrbit aims to scale production using multiple Box-E units and estimates it could take at least five years before the new drug formulations reach the market after clinical trials and regulatory approval.TrendHunter.comMicrogravity Drug Manufacturing SystemsBioOrbit, a UK space-startup, launched BOX, an orbital manufacturing unit for crystallizing biologic drugs in microgravity, which could enable reformulating intravenous medicines into self-injectable formats. The company raised £9.8 million in seed funding to further develop this technology and expand its pharmaceutical programs.Wilson Sonsini Goodrich & Rosati Professional Corporation Home PageWilson Sonsini Advises BioOrbit on $13.2 Million Seed RoundBioOrbit, a space manufacturing company, completed a $13.2 million seed round co-led by LocalGlobe and BREEGA on April 30, 2026. The company aims to build a pharmaceuticals factory in space within 10 years. Wilson Sonsini advised on the transaction.DPA MagazineUK outlines plans to bring space-manufactured drugs from orbit to marketThe UK Government announced a coordinated package of measures led by the UK Space Agency to support in-orbit manufacturing of pharmaceuticals, including regulatory guidance, case studies, a regulatory sandbox and supply-chain engagement. Officials said the package aims to clarify pathways from research to patient access, with the MHRA developing principles-based case studies. The UK Space Agency is also investing in early-stage projects, including a £250,000 feasibility study for BioOrbit.Pulse 2.0BioOrbit Closes £9.8 Million Seed Round To Manufacture Cancer Therapies In SpaceBioOrbit closed a £9.8 million seed round co-led by LocalGlobe and BREEGA to develop in-space manufacturing of cancer therapies. The company aims to produce ultra-high-concentration antibody formulations in orbit, targeting the £1 trillion global antibody market and potentially reducing hospital drug administration costs by 90%.Startups MagazineBioOrbit secures £9.8M to make drugs in spaceBioOrbit has secured £9.8 million in seed funding, the world's largest seed round for in-space manufacturing, co-led by LocalGlobe and Breega, with participation from Auxxo, Seedcamp, Type One, 7 percent, and angel investors. The funding will enable the company to scale its proprietary microgravity crystallization process, which transforms high-value protein-based drugs into injectable formats that patients can self-administer at home, potentially shifting cancer treatments from clinical settings to home-based care. The company has appointed new leadership including Dr. Molly Mulligan as President and Dr. Ken Savin as Chief Science Officer to drive its transition from breakthrough science to industrial deployment.